Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 19;22(5):1185–1196. doi: 10.1158/1078-0432.CCR-15-1015

Figure 4.

Figure 4

Effect of RG7112 in GBM patient subcutaneous xenografts on tumor growth overtime of GBM lines with various alterations. A–B) MDM2/4 and TP53 wild-type cell line, C) MDM2 amplification and TP53 wild-type cell line and D) MDM2/4 normal level and TP53 mutant cell line. E) MDM2-amplified osteosarcoma model was included as a positive control. Once tumor was established, animals were treated with RG7112 or vehicle formulation for 3 weeks. Arrows show the end of treatment period. F) Effect of RG7112 on increased life span in MDM2-amplified tumor (3731), TP53 wild-type tumors (BT139 and BT182), and TP53 mutant tumor (4339).